Logo image of ONMD

ONEMEDNET CORP (ONMD) Stock Fundamental Analysis

NASDAQ:ONMD - Nasdaq - US68270C1036 - Common Stock - Currency: USD

0.383  -0.01 (-2.37%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ONMD. ONMD was compared to 37 industry peers in the Health Care Technology industry. ONMD may be in some trouble as it scores bad on both profitability and health. ONMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONMD had negative earnings in the past year.
ONMD had a positive operating cash flow in the past year.
ONMD Yearly Net Income VS EBIT VS OCF VS FCFONMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

ONMD has a worse Return On Assets (-684.91%) than 94.59% of its industry peers.
Industry RankSector Rank
ROA -684.91%
ROE N/A
ROIC N/A
ROA(3y)-1940.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ONMD Yearly ROA, ROE, ROICONMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -2K -4K -6K -8K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONMD Yearly Profit, Operating, Gross MarginsONMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

ONMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONMD has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, ONMD has an improved debt to assets ratio.
ONMD Yearly Shares OutstandingONMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M
ONMD Yearly Total Debt VS Total AssetsONMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -45.16, we must say that ONMD is in the distress zone and has some risk of bankruptcy.
ONMD's Altman-Z score of -45.16 is on the low side compared to the rest of the industry. ONMD is outperformed by 94.59% of its industry peers.
ONMD has a debt to FCF ratio of 1.13. This is a very positive value and a sign of high solvency as it would only need 1.13 years to pay back of all of its debts.
ONMD's Debt to FCF ratio of 1.13 is amongst the best of the industry. ONMD outperforms 83.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.13
Altman-Z -45.16
ROIC/WACCN/A
WACC7.47%
ONMD Yearly LT Debt VS Equity VS FCFONMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

ONMD has a Current Ratio of 0.23. This is a bad value and indicates that ONMD is not financially healthy enough and could expect problems in meeting its short term obligations.
ONMD has a worse Current ratio (0.23) than 89.19% of its industry peers.
A Quick Ratio of 0.23 indicates that ONMD may have some problems paying its short term obligations.
ONMD has a Quick ratio of 0.23. This is amonst the worse of the industry: ONMD underperforms 89.19% of its industry peers.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
ONMD Yearly Current Assets VS Current LiabilitesONMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.92% over the past year.
Looking at the last year, ONMD shows a very strong growth in Revenue. The Revenue has grown by 140.99%.
EPS 1Y (TTM)3.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.17%
Revenue 1Y (TTM)140.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-79.12%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONMD Yearly Revenue VS EstimatesONMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 200K 400K 600K 800K 1M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONMD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONMD Price Earnings VS Forward Price EarningsONMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ONMD is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.29
EV/EBITDA N/A
ONMD Per share dataONMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONEMEDNET CORP

NASDAQ:ONMD (4/25/2025, 8:00:01 PM)

0.383

-0.01 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners15.31%
Inst Owner Change0.09%
Ins Owners38.44%
Ins Owner Change0%
Market Cap11.78M
AnalystsN/A
Price TargetN/A
Short Float %0.31%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.19
P/FCF 2.29
P/OCF 1.48
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.17
FCFY43.67%
OCF(TTM)0.26
OCFY67.69%
SpS0.05
BVpS-0.46
TBVpS-0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -684.91%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 313.97%
ROA(3y)-1940.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.13
Debt/EBITDA N/A
Cap/Depr 7255.9%
Cap/Sales 172.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z -45.16
F-Score7
WACC7.47%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)140.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-79.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-76.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y684.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1006.24%
OCF growth 3YN/A
OCF growth 5YN/A